Overview

Cisplatin is a platinum-based chemotherapy agent that is one of the most effective and widely used cytotoxic drugs in oncology. As a heavy metal complex, it functions by creating cross-links in the DNA, effectively halting the proliferation of cancer cells and inducing cell death.

Generic Name: Cisplatin
US Brand Names: Platinol®
Drug Class: Platinum Analog; Alkylating-like Agent
Route of Administration: Intravenous (IV) Infusion
FDA Approval Status: Approved for a wide range of solid tumors.

What Is It and How Does It Work? (Mechanism of Action)

Cisplatin acts as a potent DNA-damaging agent. Its mechanism is similar to that of traditional alkylating agents, but it uses platinum atoms instead of alkyl groups to create irreversible damage to the cell’s genetic material.

Molecular Activation and DNA Damage

Intracellular Activation: Cisplatin is administered as a neutral molecule. Once inside the cell, where chloride ion concentration is low, the chloride ligands are displaced by water molecules (hydrolysis). This forms highly reactive, positively charged platinum complexes.
DNA Binding: These active platinum complexes preferentially bind to the N7 position of guanine bases in the DNA.
Intra-strand Cross-links: The primary cytotoxic lesion is the formation of intra-strand cross-links between adjacent guanines on the same DNA strand. This causes a severe structural distortion in the DNA helix.
Inhibition of Replication: This distortion prevents DNA polymerase from replicating the strand and blocks RNA polymerase from transcribing genetic information.
Apoptosis Induction: The accumulation of unrepaired DNA damage triggers various cellular signaling pathways that ultimately lead to programmed cell death (apoptosis), regardless of the cell cycle phase.

FDA-Approved Clinical Indications

Cisplatin is a backbone component of multi-drug regimens for several curable and advanced cancers.

Oncological Uses

Testicular Cancer: Used in highly curative protocols (e.g., BEP regimen).
Ovarian Cancer: Used in combination with paclitaxel for metastatic or recurrent epithelial ovarian cancer.
Bladder Cancer (Urothelial Carcinoma): Used in metastatic disease (e.g., MVAC or Gem-Cis regimens).
Head and Neck Cancers: Used in definitive chemoradiation protocols.
Non-Small Cell Lung Cancer (NSCLC): Used in combination regimens (neoadjuvant, adjuvant, and metastatic).
Cervical Cancer: Used in combination with radiation.

Non-oncological Uses

None currently approved.

Dosage and Administration Protocols

Cisplatin dosing varies significantly based on the protocol and tumor type. Due to its high toxicity, it requires mandatory pre- and post-hydration.

ndication	Route	Dose	Frequency	Infusion Time	Notes
Various solid tumors	IV	50–100 mg/m²	Every 3–4 weeks	1–6 hours	Hydration critical to reduce nephrotoxicity
Testicular cancer	IV	20 mg/m² daily	5 consecutive days every 3–4 weeks	1 hour	In combination with other agents

Dose Adjustments

Renal Insufficiency: Cisplatin is highly nephrotoxic and its clearance depends on kidney function. The dose is strictly withheld if the serum creatinine is above the institutional threshold (e.g., > 1.5 mg/dL) or if Creatinine Clearance is below 50-60 mL/min.
Hepatic Insufficiency: No specific dose adjustment is universally required, as the drug is mainly excreted by the kidneys.

Clinical Efficacy and Research Results

Cisplatin’s efficacy is unparalleled in certain tumor types, contributing to high cure rates (2020-2025 context).

Testicular Cancer Cure Rate: The introduction of Cisplatin has raised the cure rate for metastatic non-seminomatous testicular cancer from below 10% to over 80%, establishing it as one of oncology’s greatest triumphs.
Urothelial Carcinoma: In the neoadjuvant setting, Cisplatin-based chemotherapy (MVAC or Gem-Cis) achieves pathologic complete response (pCR) rates of approximately 30% to 40%.
NSCLC Adjuvant Benefit: Randomized trials confirm that Cisplatin-based adjuvant chemotherapy reduces the risk of death by approximately 11% in patients with resected stage II and III NSCLC.
Ovarian Cancer Survival: The combination of Cisplatin and a taxane yields a 5-year survival rate of approximately 40% for advanced epithelial ovarian cancer.

Safety Profile and Side Effects

Black Box Warning

Nephrotoxicity: Dose-related and cumulative renal insufficiency is common and can be irreversible. Aggressive hydration is mandatory.
Ototoxicity: Severe, irreversible hearing loss (sensorineural toxicity) and tinnitus can occur, often cumulative.
Myelosuppression: Bone marrow suppression, particularly leukopenia and thrombocytopenia.
Nausea/Vomiting: Severe, persistent, and highly emetogenic.

Common Side Effects (>10%)

Gastrointestinal: Severe, intractable nausea and vomiting.
Renal: Electrolyte wasting (hypomagnesemia, hypocalcemia, hypokalemia).
Systemic: Fatigue, malaise, and peripheral neuropathy (numbness/tingling).

Serious Adverse Events

Irreversible Ototoxicity: Permanent high-frequency hearing loss.
Anaphylactic-like Reactions: Acute hypersensitivity reactions can occur minutes after starting the infusion.
Severe Neurotoxicity: Peripheral neuropathy that is dose-limiting and often permanent.

Management Strategies

Hydration: Mandatory 1 to3 liters of IV saline pre- and post-infusion, often with magnesium and potassium supplementation.
Antiemetics: Multi-drug anti-nausea prophylaxis (NK1 inhibitor, 5-HT3 antagonist, and steroids) is required.

Connection to Stem Cell and Regenerative Medicine

Nephroprotection Research: Research is heavily focused on regenerative strategies to protect renal stem cells and nephrons from Cisplatin-induced damage, often through novel drug delivery or co-administration of cytoprotectants.
Immune Regeneration: Cisplatin-induced DNA damage can act as a trigger, enhancing the visibility of tumor antigens to the immune system. Current Immunotherapy research is combining low-dose Cisplatin with checkpoint inhibitors to prime the regenerative T-cell response in tumors that are normally immune-cold.

Patient Management & Practical Recommendations

Pre-treatment Tests to Be Performed

Renal Function: Mandatory Serum Creatinine, BUN, and Creatinine Clearance before every cycle.
Audiometry: Baseline hearing test (audiogram) is required, especially if repeated doses are planned.
Labs: Electrolytes (Magnesium, Potassium, Calcium).

Precautions During Treatment

Hydration: Ensure the patient maintains high oral fluid intake the day before and several days after the infusion.
Extravasation: Cisplatin is an irritant; administer via a large, well-functioning IV line or central venous catheter.

Do’s and Don’ts

DO: Report any ringing in the ears (tinnitus) or difficulty hearing high-pitched sounds immediately.
DO: Take all prescribed anti-nausea medications on time, even if you feel fine.
DO: Report any numbness or tingling in the hands or feet, as this may be cumulative.
DON’T: Use other known nephrotoxic drugs (like NSAIDs or aminoglycosides) during the treatment period without consulting your oncologist.
DON’T: Confuse Cisplatin with Carboplatin; they have different dosing and toxicity profiles.
DON’T: Allow the infusion to proceed if you have not been adequately pre-hydrated.

Legal Disclaimer

This guide is for informational purposes only and is intended for international patients and healthcare professionals. It does not replace professional medical advice, diagnosis, or treatment. Dosing and protocols may vary by patient status and local regulatory guidelines. Always consult with a qualified oncologist or healthcare provider regarding specific medical conditions.